Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 895-902

  Kontani, Keiichi ^a   Teramoto, Koji ^b   Ozaki, Yoshitomo ^b   Sawai, Satoru ^b   Tezuka, Noriaki ^b   Ishida, Hideaki ^b   Kajino, Kiichi ^b   Fujino, Shozo ^b   Yamauchi, Akira ^a   Taguchi, Osamu ^c   Kannagi, Reiji ^c   Yokomise, Hiroyasu ^a   Ogasawara, Kazumasa ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer immunotherapy; Cytotoxic t lymphocyte; Dendritic cell; Vaccine

Indexed keywords

ANTIBODY; CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; PENICILLIN DERIVATIVE;

ADOPTIVE IMMUNOTHERAPY; AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; STREPTOCOCCUS PYOGENES; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

AGED; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD40; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PENICILLINS; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34249944841     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.895     Document Type: Article

References (49)

1. Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287, 1997.
2. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998. (Pubitemid 28155090)
3. Lanzavecchia A and Sallusto F: Regulation of T cell immunity by dendritic cells. Cell 106: 263-266, 2001. (Pubitemid 32772609)
4. Kontani K, Taguchi O, Narita T, et al: Autologous dendritic cells or cells expressing both B7-1 and MUC1 can rescue tumor-specific cytotoxic T lymphocytes from MUC1-mediated apoptotic cell death. J Leukocyte Biol 68: 225-232, 2000.
5. Kontani K, Taguchi O, Sawai S, et al: Novel vaccination protocol consisting of injecting MUC1 DNA and non-primed dendritic cells at the same region greatly enhanced MUC1-specific anti-tumor immunity in a murine model. Cancer Gene Ther 9: 330-337, 2002. (Pubitemid 34289451)
6. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998. (Pubitemid 28144092)
7. Murphy GP, Tjoa BA, Simmons SJ, et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 73-78, 1999. (Pubitemid 29011020)
8. Simmons SJ, Tjoa BA, Rogers M, et al: GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. Prostate 39: 291-297, 1999. (Pubitemid 29244504)
9. Thurner B, Haendle I, Roder C, et al: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678, 1999. (Pubitemid 30002348)
10. Rieser C, Ramoner R, Holtl R, et al: Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 63: 151-159, 1999. (Pubitemid 30083819)
11. + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165: 3492-3496, 2000.
12. Toungouz M, Libin M, Bulte F, et al: Transient expansion of peptide-specific lymphocytes producing IFN- after vaccination with dendritic cells pulsed with MAGE peptides in patients with MAGE-A1/A3-positive tumors. J Leukocyte Biol 69: 937-943, 2001. (Pubitemid 32577895)
13. Fong L, Brockstedt D, Benike C, Wu L and Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 66: 4254-4259, 2001. (Pubitemid 32224961)
14. Sinkovics JG and Horvath JC: Vaccination against human cancers. Int J Oncol 16: 81-96, 2000.
15. Kontani K, Taguchi O, Sawai S, et al: Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 12: 493-502, 2003.
16. Hersey P, Menzies SW, Halliday GM, et al: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53: 125-134, 2004. (Pubitemid 38161219)
17. Vilella R, Benitez D, Mila J, et al: Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 53: 651-658, 2004. (Pubitemid 38858339)
18. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3: 483-490, 1997. (Pubitemid 27158075)
19. Almand B, Resser JR, Lindman, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000. (Pubitemid 30305068)
20. Kiertscher SM, Steven JL, Dubinett M and Roth MD: Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164: 1269-1276, 2000. (Pubitemid 30067239)
21. Mehrotra S, Stevens R, Zengou R, et al: Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res 63: 5607-5614, 2003. (Pubitemid 37139885)
22. Yang AS and Lattime EC: Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63: 2150-2157, 2003. (Pubitemid 36538620)
23. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32, 2001.
24. Wolf AM, Wolf D, Steurer M, et al: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003. (Pubitemid 36182591)
25. Chambers CA, Kuhns MS, Egen JG and Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594, 2001. (Pubitemid 32368046)
26. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
27. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al:Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-832, 2001. (Pubitemid 32983017)
28. Yang Y, Huang CT, Huang X and Pardoll DM: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5: 508-515, 2004. (Pubitemid 38660463)
29. Nakahara S, Tsunoda T, Baba T, Asabe S and Tahara H: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63: 4112-4118, 2003. (Pubitemid 36917935)
30. Vidalain P-O, Azocar O, Yagita H, Rabourdin-Combe C and Servet-Delprat C: Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 167: 3765-3772, 2001. (Pubitemid 32910822)
31. Verdijk RM, Mutis T, Esendam B, et al: Polyriboinosinic polyribocytidylic acid (Poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 163: 57-61, 1999. (Pubitemid 29295824)
32. Sparwasser T, Koch E-S, Vabulas RM, et al: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28: 2045-2054, 1998. (Pubitemid 28271721)
33. Itoh T, Ueda Y, Okugawa K, et al: Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 52: 207-214, 2003. (Pubitemid 36535280)
34. Nakamura I, Kajino K, Bamba H, et al: Phenotypic stability of mature dendritic cells tuned by TLR or CD40 to control the efficiency of cytotoxic T cell priming. Microbiol Immunol 48: 211-219, 2004. (Pubitemid 38405084)
35. Ozaki Y, Kontani K, Teramoto K, et al: Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for the use in cancer immunotherapy. Biochem Biophys Res Commun 317: 1089-1095, 2004. (Pubitemid 38496421)
36. Valmori D, Lienard D, Waanders G, et al: Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 57: 735-741, 1997. (Pubitemid 27085659)
37. Tanaka F, Fujie T, Tahara K, et al: Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57: 4465-4468, 1997. (Pubitemid 27441045)
38. Teramoto K, Kontani K, Taguchi O, et al: DNA encoding a pan-MHC class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Cancer Res 63: 7920-7925, 2003. (Pubitemid 37466728)
39. Yang S, Yang Y, Raycraft J, et al: Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci USA 101: 4990-4995, 2004. (Pubitemid 38469190)
40. Banchereau J, Briere F, Caux C, et al: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000. (Pubitemid 30365397)
41. Gimmi CD, Freeman GJ, Gribben JG, Gray G and Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90: 6586-6590, 1993. (Pubitemid 23207258)
42. Lenschow DJ and Bluestone JA: T cell co-stimulation and in vivotolerance. Curr Opin Immunol 5: 747-752, 1993.
43. Larsen CP and Pearson TC: The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 9: 641-647, 1997. (Pubitemid 27485291)
44. Bonifaz L, Bonnyay D, Mahnke K, et al: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638, 2002. (Pubitemid 36026474)
45. Vicari AP, Chiodoni C, Vaure C, et al: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196: 541-549, 2002.
46. Brossart P, Zobywalski A, Grunebach F, et al: Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 60: 4485-4492, 2000. (Pubitemid 32103629)
47. + T cell expansion with variable dependence on type I IFN. J Exp Med 199: 775-784, 2004.
48. Cerundolo V, Hermans IF and Salio M: Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5: 7-10, 2004. (Pubitemid 38081459)
49. Martin-Fontecha A, Sebastiani S, Hopken UE, et al: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621, 2003. (Pubitemid 37040395)